Nyhetsarkiv for Forskningsgruppe for hjernekreft immunologi og terapi

This phase IB/II trial is designed to investigate the safety and survival benefits for patients with recurrent glioblastoma with unmethylated MGMT promoter treated with Bortezomib and Temozolomide in a specific schedule.